effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: a double-blind, randomized, placebo-controlled live sub-study

The glucagon-like peptide-1 analog liraglutide increases heart rate and be associated with more cardiac events in chronic heart failure (chf) patients. we studied whether this could be ascribed to effects on myocardial glucose uptake (mgu), myocardial blood flow (mbf) and mbf reserve (mfr). chf patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (n = 18) 1.8 mg once daily or placebo (n = 18) for 24 weeks in a double-blinded design. changes in mgu during an oral glucose tolerance test (ogtt) and changes in mbf and mfr from baseline to follow-up were measured quantitatively by 18f-fdg and 15o-h2o positron emission tomography. compared with placebo, liraglutide reduced weight (p = 0.03), hba1c (p = 0.03) and the 2-hour glucose value during the ogtt (p = 0.004). despite this, changes in mgu (p = 0.98), mbf (p = 0.76) and mfr (p = 0.89) from baseline to follow-up did not differ between groups. furthermore, there was no association between the level of insulin resistance at baseline and changes in mgu in patients treated with liraglutide. liraglutide did not affect mgu, mbf, or mfr in non-diabetic chf patients. any potential increase in cardiac events in these patients seems not to involve changes in mgu, mbf, or mfr. trial registry: http://www.clinicaltrials.org . identifier: nct01472640. url: https://clinicaltrials.gov/ct2/show/nct01472640?term=nct01472640&rank=1